A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstruation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Clinicians and patients desiring amenorrhea for therapeutic or social reasons will find continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol to be an attractive oral contraceptive dosing option. Although other formulations of oral contraceptives can be dosed in a continuous manner off-label, the convenience of a 28-day dose pack represents a major advance that will likely increase acceptability of the strategy. The availability of FDA-approved continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol will help mainstream continuous oral contraception in the same way that Preveri™ and Plan B® helped legitimize and mainstream emergency contraception. Patients wishing to use continuous 90 μg levonorgestrel/20 μg ethinyl estradiol must recognize and accept that unscheduled breakthrough bleeding is typical during the first four to six cycles of use. Control of cycle-related symptoms may emerge as an off-label indication for use.

Original languageEnglish (US)
Pages (from-to)183-195
Number of pages13
JournalDrugs of Today
Volume44
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Levonorgestrel
Menstruation
Contraception
Ethinyl Estradiol
Oral Contraceptives
Postcoital Contraception
Off-Label Use
Metrorrhagia
Amenorrhea
levonorgestrel drug combination ethinyl estradiol
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstruation. / Jensen, Jeffrey.

In: Drugs of Today, Vol. 44, No. 3, 03.2008, p. 183-195.

Research output: Contribution to journalArticle

@article{d306a81366dd4a42933bc7d5b099bde8,
title = "A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstruation",
abstract = "Clinicians and patients desiring amenorrhea for therapeutic or social reasons will find continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol to be an attractive oral contraceptive dosing option. Although other formulations of oral contraceptives can be dosed in a continuous manner off-label, the convenience of a 28-day dose pack represents a major advance that will likely increase acceptability of the strategy. The availability of FDA-approved continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol will help mainstream continuous oral contraception in the same way that Preveri™ and Plan B{\circledR} helped legitimize and mainstream emergency contraception. Patients wishing to use continuous 90 μg levonorgestrel/20 μg ethinyl estradiol must recognize and accept that unscheduled breakthrough bleeding is typical during the first four to six cycles of use. Control of cycle-related symptoms may emerge as an off-label indication for use.",
author = "Jeffrey Jensen",
year = "2008",
month = "3",
doi = "10.1358/dot.2008.44.3.1197950",
language = "English (US)",
volume = "44",
pages = "183--195",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "3",

}

TY - JOUR

T1 - A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstruation

AU - Jensen, Jeffrey

PY - 2008/3

Y1 - 2008/3

N2 - Clinicians and patients desiring amenorrhea for therapeutic or social reasons will find continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol to be an attractive oral contraceptive dosing option. Although other formulations of oral contraceptives can be dosed in a continuous manner off-label, the convenience of a 28-day dose pack represents a major advance that will likely increase acceptability of the strategy. The availability of FDA-approved continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol will help mainstream continuous oral contraception in the same way that Preveri™ and Plan B® helped legitimize and mainstream emergency contraception. Patients wishing to use continuous 90 μg levonorgestrel/20 μg ethinyl estradiol must recognize and accept that unscheduled breakthrough bleeding is typical during the first four to six cycles of use. Control of cycle-related symptoms may emerge as an off-label indication for use.

AB - Clinicians and patients desiring amenorrhea for therapeutic or social reasons will find continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol to be an attractive oral contraceptive dosing option. Although other formulations of oral contraceptives can be dosed in a continuous manner off-label, the convenience of a 28-day dose pack represents a major advance that will likely increase acceptability of the strategy. The availability of FDA-approved continuous-use 90 μg levonorgestrel/20 μg ethinyl estradiol will help mainstream continuous oral contraception in the same way that Preveri™ and Plan B® helped legitimize and mainstream emergency contraception. Patients wishing to use continuous 90 μg levonorgestrel/20 μg ethinyl estradiol must recognize and accept that unscheduled breakthrough bleeding is typical during the first four to six cycles of use. Control of cycle-related symptoms may emerge as an off-label indication for use.

UR - http://www.scopus.com/inward/record.url?scp=43449125023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449125023&partnerID=8YFLogxK

U2 - 10.1358/dot.2008.44.3.1197950

DO - 10.1358/dot.2008.44.3.1197950

M3 - Article

C2 - 18536780

AN - SCOPUS:43449125023

VL - 44

SP - 183

EP - 195

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 3

ER -